Stephen Hoge, the President of $MRNA, sold 53,336 shares of the company on 05-15-2026 for an estimated $2,581,462. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.5% of their shares of this class of stock. Following this trade, they now own 1,477,997 shares of this class of $MRNA stock.
$MRNA Insider Trading Activity
$MRNA insiders have traded $MRNA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHEN HOGE (President) has made 0 purchases and 2 sales selling 213,345 shares for an estimated $10,396,301.
- SHANNON THYME KLINGER (Chief Legal Officer) sold 13,885 shares for an estimated $726,046
- NOUBAR AFEYAN sold 23,853 shares for an estimated $703,305
- ABBAS HUSSAIN has made 0 purchases and 2 sales selling 6,186 shares for an estimated $278,862.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MRNA Hedge Fund Activity
We have seen 375 institutional investors add shares of $MRNA stock to their portfolio, and 326 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 17,626,713 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $848,197,429
- CAPITAL WORLD INVESTORS added 5,869,654 shares (+45.8%) to their portfolio in Q1 2026, for an estimated $282,447,750
- BLACKROCK, INC. removed 2,869,857 shares (-8.8%) from their portfolio in Q1 2026, for an estimated $138,097,518
- GOLDMAN SACHS GROUP INC added 2,653,078 shares (+67.2%) to their portfolio in Q1 2026, for an estimated $127,666,113
- WELLINGTON MANAGEMENT GROUP LLP added 2,274,302 shares (+2730.4%) to their portfolio in Q1 2026, for an estimated $109,439,412
- TWO SIGMA INVESTMENTS, LP added 1,744,308 shares (+23.8%) to their portfolio in Q1 2026, for an estimated $83,936,100
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,560,559 shares (-96.6%) from their portfolio in Q1 2026, for an estimated $75,094,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MRNA Analyst Ratings
Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
- Leerink Partners issued a "Underperform" rating on 11/21/2025
To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.
$MRNA Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 9 analysts offer price targets for $MRNA in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Luca Issi from RBC Capital set a target price of $38.0 on 05/04/2026
- Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
- Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
- Eliana Merle from UBS set a target price of $45.0 on 05/04/2026
- Eliana Merle from Barclays set a target price of $48.0 on 04/02/2026
- Edward Tenthoff from Piper Sandler set a target price of $69.0 on 02/23/2026
- Andrew Tsai from Jefferies set a target price of $30.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
